Asset Details
Do you wish to reserve the book?
Recombinant CD80 fusion protein combined with discoidin domain receptor 1 inhibitor for cancer treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recombinant CD80 fusion protein combined with discoidin domain receptor 1 inhibitor for cancer treatment
Do you wish to request the book?
Recombinant CD80 fusion protein combined with discoidin domain receptor 1 inhibitor for cancer treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recombinant CD80 fusion protein combined with discoidin domain receptor 1 inhibitor for cancer treatment
2025
Overview
Immune checkpoint inhibitors (ICIs) have significantly advanced the field of cancer immunotherapy. However, clinical data has shown that many patients have a low response rate or even resistance to immune checkpoint inhibitor alone. The underlying reasons for its poor efficacy include the deficiency of immune infiltration and effective CD28/CD80 costimulatory signal in tumor. Discoidin domain receptor 1 (DDR1) has been reported to be negatively related to immune cell infiltration in tumors. Herein, we constructed a soluble fusion protein using CD80, the natural ligand of CD28, in combination with DDR1 inhibitor. Our results demonstrated that CD80-Fc effectively activated T cells and inhibited tumor growth in vivo, even in tumors with poor efficacy of ICIs. Importantly, CD80-Fc fusion protein had a milder affinity against the targets which suggested a potential higher safety than CD28 agonists. Further, in order to promote tumor immune infiltration, we attempted to combine CD80-Fc fusion protein with DDR1 inhibitor for treatment. Our results indicated that using CD80-Fc fusion protein along with DDR1 inhibitor significantly promoted T cell infiltration in tumor microenvironment and more strongly inhibited tumor growth. Therefore, the combination use of CD80 fusion protein and DDR1 inhibitor could become an effective tumor immunotherapy strategy, potentially benefiting a larger number of patients.
Key points
• We successfully constructed, expressed, and purified the recombinant CD80-Fc fusion protein
• We demonstrated that CD80-Fc fusion protein has good safety and anti-tumor activity
• We demonstrated that using CD80-Fc fusion protein along with DDR1 inhibitor can significantly promote immune infiltration of T cells in tumor microenvironment and more strongly inhibit tumor growth
Publisher
Springer Berlin Heidelberg,Springer Nature B.V,Springer
Subject
/ Biomedical and Life Sciences
/ Biotechnological Products and Process Engineering
/ Cancer
/ DDR1
/ Discoidin Domain Receptor 1 - antagonists & inhibitors
/ domain
/ Female
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - pharmacology
/ Immunoglobulin Fc Fragments - genetics
/ ligands
/ Mice
/ Microbial Genetics and Genomics
/ Patients
/ Proteins
/ Recombinant Fusion Proteins - genetics
/ Recombinant Fusion Proteins - pharmacology
/ Recombinant Fusion Proteins - therapeutic use
/ T cell costimulatory signals
/ T-Lymphocytes - drug effects
/ Tumor Microenvironment - drug effects
/ Tumors
